Shaping a new era of global health investment, policy, planning and prevention
AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.
Our advocacy takes place:
infographic
Official characterizations of the HIV response as “doing very good” warrant a closer look at the data. AVAC’s analysis of PEPFAR prevention figures shows PrEP initiations declined 41% in one year, with women and men each seeing drops exceeding 50%. Data on key populations remains unavailable.
report
This report highlights AVAC’s role as a trusted voice, a translator of science and catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization.
article
AVAC’s formal input submitted on the re-competition of the NIAID HIV/AIDS Clinical Trials Networks. The recommendations were informed by the People’s Research Agenda (PRA), a comprehensive framework developed through consultations with over 130 community representatives across 23 countries.
Percentage of key population-serving implementing partners that have reported full or partial termination of the provision of KP services due to US funding cuts (as of April 2025).
Accelerating the development and delivery of STI prevention.
Using data for smarter advocacy and high-impact campaigns.
Developing an Africa-centered network dedicated to accelerating HIV prevention research, and advancing equitable access to proven HIV prevention products.
In a landmark moment, South Africa today became the 9th African country to introduce lencapavir (LEN) for HIV prevention. South Africa’s introduction of LEN is especially significant given the country’s central role in shaping the regional HIV response and the global PrEP market. As the largest PrEP market in the world, South Africa’s leadership can help drive the demand, volume, market confidence and lower prices needed to accelerate equitable access across the continent and the world.
On Wednesday, May 20, AVAC’s Mitchell Warren was joined by Nicholas Enrich, author of Into the Wood Chipper and former global health lead at USAID, and Rosemary Mburu, Executive Director of WACI Health, for Inside the Decisions that Changed Global Health: An AVAC Conversation with Nicholas Enrich. Curing the call, Enrich shared an inside perspective on the decisions that led to the dismantling of USAID and the foreign aid freeze and what they mean for global health today.
This is the second in a series of two webinars providing an overview of what is happening now in countries to HIV prevention services for KPs, featuring tools and analyses produced by GBGMC, in partnership with Access Bridge to support advocacy and planning at country levels.